stock
LYEL · Lyell Immunopharma, Inc.
What Lyell Immunopharma, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live LYEL price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on LYEL.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 24,505,141 as of 2026-08-03 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- -949981.5%
- Net
- -920285.2%
Returns
- ROE
- -106.3%
- ROA
- -79.9%
Health
- Current ratio
- 5.4x
- Debt/equity
- —
Deep value
- NCAV
- $136.20M
- NCAV per share
- $5.56
- Price/NCAV
- Locked
- NNWC
- -$4.35M
- NNWC per share
- -$0.18
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $4,000 | —Gross profit: unreported by this company. | -$47.34M | -$44.76M | 10-Q filed 2026-08-06 |
| 2026-03-31 | $2,000 | —Gross profit: unreported by this company. | -$44.26M | -$24.15M | 10-Q filed 2026-05-06 |
| 2025-12-31 | $6,000 | —Gross profit: unreported by this company. | -$127.64M | -$140.72M | DEF 14A filed 2026-04-24 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | $15,000 | —Gross profit: unreported by this company. | -$37.25M | -$38.85M | 10-Q filed 2025-11-12 |
| 2025-06-30 | $8,000 | —Gross profit: unreported by this company. | -$47.14M | -$42.68M | 10-Q filed 2026-08-06 |
| 2025-03-31 | $7,000 | —Gross profit: unreported by this company. | -$57.37M | -$52.20M | 10-Q filed 2026-05-06 |
| 2024-12-31 | $11,000 | —Gross profit: unreported by this company. | -$201.15M | -$191.94M | DEF 14A filed 2026-04-24 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | $34,000 | —Gross profit: unreported by this company. | -$50.51M | -$44.58M | 10-Q filed 2025-11-12 |
- Assets
- $311.15M
- Equity
- $233.81M
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | $36,000 | -$269.40M | -$274.45M | -$150.80M |
| 2024-12-31 | $61,000 | -$358.75M | -$342.99M | -$162.86M |
| 2023-12-31 | $130,000 | -$247.01M | -$234.63M | -$166.38M |
| 2022-12-31 | $84.68M | -$187.06M | -$183.12M | -$193.83M |
| 2021-12-31 | $10.65M | -$214.78M | -$250.22M | -$191.75M |
| 2020-12-31 | $7.76M | -$211.94M | -$204.47M | -$212.35M |
| 2019-12-31 | $657,000 | -$102.09M | -$129.38M | $23.43M |
Company filings
since Mon Jul 13 · 1 offering filing in 12 months
events
5% owners ()
Foresite Capital Fund IV, L.P.
Stake update
Innovative Cellular Therapeutics Holdings Limited
Stake update
ARCH Venture Fund IX, L.P.
Stake update
MWG Caph Ltd
Stake update
Explore Investments LLC
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Shook David
Chief Medical Officer
Sale$6,350Sep 10, 7:37 PM ET
Seely Lynn
President and CEO, Director
Sale$149,013Aug 25, 4:06 PM ET
Hill Stephen J.
Chief Operating Officer
Sale$15,369Aug 25, 4:05 PM ET
Lee Gary K.
Chief Scientific Officer
Sale$22,642Aug 25, 4:03 PM ET
Bulis Veronica Sanchez
VP, Corporate Controller
Sale$8,905Aug 11, 4:21 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
News
Stories that named LYEL, and the market events around them.
Sign in to see thisBoard
The LYEL board could not be loaded.
Retry the LYEL boardnakagai
Signals on LYEL come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the LYEL board